Luca Arecco, MD, University of Genoa, Genova, Italy, discusses the impact of hormone receptor status and tumor subtypes in young patients aged 40 or younger with early breast cancer, due to BRCA mutations. The impact of hormone receptor status is different to those with sporadic disease. Patients were divided into luminal A and B, triple negative, and HER2-positive (HER2+) subtypes, in which results surprisingly revealed those with luminal A disease had the worst prognosis in terms of disease-free survival (DFS). This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
